Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Reveals Plans For Unitary SPC & Review Of Compulsory Licensing

SPC Plans Boosted By Go-Ahead For Unified Patent Court

Executive Summary

The EU has announced two separate legal initiatives, one that would improve IP protections, and another that could weaken them in the event of a future health crisis.

You may also be interested in...



Streamlined EU Supplementary Protection Certificate System Moves Ahead

A parliamentary committee says the proposals will remove the fragmentation in the EU SPC system and bring predictability for both the innovative and generics industry.

EU Explains Plans For Use Of ‘Last Resort’ Compulsory Licensing

The first stage of the EU’s proposal to revamp the compulsory licensing system and prepare the bloc for future health crises is almost complete. The next steps are to publish an impact assessment, run a public consultation, and produce a draft regulation by the first quarter of 2023.

EU Firms Up Plans For Unitary Supplementary Protection Certificates

A unified system for granting SPCs would significantly reduce the burden of seeking protection in up to 27 different EU countries, and would sit well alongside Europe's future unitary patent system, says the European Commission. It now preparing an impact assessment for the proposal.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151652

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel